2024-09-03 - Analysis Report
## CL Stock Analysis: 

**Company:** Colgate-Palmolive Company (CL), a leading global consumer products company offering oral care, personal care, home care, and pet nutrition products.

**1. Performance vs S&P 500 (VOO):**

* **Cumulative Return:** CL: 59.01%, VOO: 89.66%
* **Underperformance:** CL has underperformed VOO by **-30.65%** (relative to the historical range, this is at the 30.92% percentile).

**2. Recent Price Movement:**

* **Closing Price:** $106.5
* **Moving Averages:**
    * 5-day: $105.82
    * 20-day: $103.2
    * 60-day: $99.25

**3. Technical Indicators:**

* **RSI:** 80.28 (overbought territory)
* **PPO:** 0.21 (positive, indicating potential bullish momentum)
* **Delta_Previous_Relative_Divergence:** -6.87 (short-term downtrend)
* **Expected_Return:** 11.96% (maximum projected return over 5 years)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-26 | 0.89 | 5.06 B$ |
| 2024-04-26 | 0.83 | 5.07 B$ |
| 2023-10-27 | 0.86 | 4.92 B$ |
| 2023-07-28 | 0.61 | 4.82 B$ |
| 2024-07-26 | 0.61 | 4.82 B$ |

* **Latest Earnings:** EPS of 0.89 and revenue of 5.06 B$ for Q2 2024. 
* **Outlook:** The company has a history of consistent revenue growth, although earnings have been slightly volatile. The recent earnings have been in line with analysts' expectations.

**5. Overall Analysis:**

* CL has underperformed the S&P 500 in the long term, despite showing signs of recent price strength. 
* Technical indicators suggest the stock is overbought, but its PPO suggests potential bullish momentum.
* CL's earnings have been consistent and in line with expectations, demonstrating strong fundamental performance.

**6. Summary:**

While CL has lagged behind the broader market in the past, its recent price action and solid earnings suggest potential for future growth. However, the overbought RSI and short-term downtrend in relative divergence suggest caution is warranted. Investors should closely monitor these indicators and the company's future earnings releases for further guidance.
